Selecting a clinical data management platform is ultimately a regulatory decision as much as a technology one. A platform that looks capable during a demo still has to hold up under FDA scrutiny years later, when a submission’s underlying data is reviewed for integrity and traceability. This article walks through four things sponsors are generally advised to confirm before selecting a platform: 21 CFR Part 11 compliance, audit trail completeness, CDISC output capability, and a vendor’s own audit history.
21 CFR Part 11: The Baseline Requirement
21 CFR Part 11 sets the FDA’s criteria for treating electronic records and electronic signatures as trustworthy and equivalent to paper records and handwritten signatures. It applies to electronic records created, modified, maintained, or transmitted by FDA-regulated entities, which in practice covers EDC systems, and extends to a CTMS when that system is used to satisfy a record-keeping requirement rather than serving purely as an internal planning tool.
For a data management platform, relevant Part 11 controls generally include validated processes, controlled system access, and electronic signatures that are attributable to specific individuals and securely linked to the associated electronic records. Sponsors are typically advised to ask a vendor for documented evidence of system validation rather than a general compliance statement, since validation status is what FDA reviewers and inspectors will expect to see referenced during an inspection.
Audit Trail Completeness: What to Verify
An audit trail, as FDA’s guidance for computerized systems describes it, is a secure, computer-generated, time-stamped electronic record that allows reconstruction of the course of events relating to the creation, modification, and deletion of a record. Meeting this definition on paper is different from meeting it in practice, so sponsors are generally encouraged to look at specific components rather than accepting a platform’s audit trail claim at face value.
Relevant components include secure, computer-generated time stamps, a recorded user identity for changes, a captured reason for change where applicable, and protections that prevent users from modifying the audit trail itself. A platform that logs some changes but not others — for example, capturing data entry but not query resolution — generally leaves a gap that becomes harder to explain during a later inspection than it would have been to prevent at the design stage.
How Platform Infrastructure Supports These Requirements in Practice
These compliance elements are not abstract for sponsors comparing clinical data management services — they show up in the specific technology and quality infrastructure a provider has in place. Tigermed has also developed and operated Clinflash EDC, which was launched in 2014 and has been used in more than 350 clinical research projects according to company disclosures.
On the quality side, Tigermed’s QA function operates independently of its clinical operations teams and reports more than 40 in-house auditors, with audit services covering Phase I–IV clinical trials, data management, and trial master file review, among other areas. According to the company, roughly 65% of its auditors have six or more years of auditing experience. This kind of independent QA structure is relevant to Part 11 and audit trail questions specifically, since ongoing internal auditing is one of the mechanisms that helps confirm a platform’s controls are functioning as documented, not just designed correctly on paper.
CDISC Output: A Non-Negotiable for FDA Submissions
FDA’s standardized study data requirements apply to specified submissions and study types, with standards including SDTM, ADaM, and SEND; sponsors should confirm the applicable FDA data standards and implementation timelines for each submission. A data management platform that cannot produce or export data cleanly into these formats creates additional downstream work converting legacy or non-standard data structures before submission.
Sponsors evaluating platforms are generally advised to ask specifically how SDTM and ADaM datasets are generated — whether datasets are generated natively, through a defined mapping and validation process, or through downstream statistical programming workflows, with tools such as Pinnacle 21 used separately for conformance checking. Define.xml files and reviewer’s guides also need to accompany these datasets, so a platform’s compatibility with this broader documentation package is worth confirming alongside the core data formats themselves.
Vendor Audit History: What It Reveals
A vendor’s compliance credentials provide additional context for evaluating how its quality systems and regulated processes perform in practice. Sponsors are generally encouraged to ask a prospective data management partner about its own history of vendor audits and health authority inspections, rather than relying solely on marketing claims about compliance.
Tigermed reports having supported more than 3700 onsite audits and over 100 vendor audits, and describes assisting clients with NMPA onsite inspections and GCP, GLP, and GMP audits as part of its quality assurance service. In its 2025 annual results, the company also reported achieving what it described as a “zero-defect” outcome in an FDA inspection. Figures and outcomes like these do not guarantee a specific future inspection result, but they give sponsors a documented starting point for evaluating a vendor’s compliance track record rather than an unverified assurance.
Weighing the Full Compliance Picture
None of these four factors works well in isolation. A platform with strong Part 11 controls but incomplete audit trails still creates risk, and conformant CDISC datasets do not by themselves establish the strength of a vendor’s audit history. Sponsors comparing a clinical data management platform are generally best served by requesting specific documentation across all four areas — validation records, audit trail specifications, CDISC output samples, and audit or inspection history — rather than treating any single credential as sufficient on its own.
Companies such as Tigermed, which report both EDC technology infrastructure and an independent, actively staffed QA and audit function, illustrate one way these elements can be organized together. As with any platform decision, sponsors are advised to confirm current validation status and request references specific to their submission type before making a final selection.
